Janux Therapeutics Stock Piotroski F Score

JANX Stock  USD 40.18  5.03  11.13%   
This module uses fundamental data of Janux Therapeutics to approximate its Piotroski F score. Janux Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Janux Therapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Janux Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Janux Therapeutics Altman Z Score, Janux Therapeutics Correlation, Janux Therapeutics Valuation, as well as analyze Janux Therapeutics Alpha and Beta and Janux Therapeutics Hype Analysis.
For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.
  
At this time, Janux Therapeutics' Net Debt is fairly stable compared to the past year. Debt To Equity is likely to rise to 0.07 in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 14.9 M in 2024. At this time, Janux Therapeutics' Price Book Value Ratio is fairly stable compared to the past year. Ebt Per Ebit is likely to rise to 1.14 in 2024, despite the fact that Free Cash Flow Yield is likely to grow to (0.11).
At this time, it appears that Janux Therapeutics' Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Poor
Current Return On Assets

Negative

Focus
Change in Return on Assets

Decreased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Improving

Focus
Asset Turnover Growth

Decrease

Focus
Current Ratio Change

Increase

Focus
Long Term Debt Over Assets Change

N/A

Focus
Change In Outstending Shares

Increase

Focus
Change in Gross Margin

Increase

Focus

Janux Therapeutics Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Janux Therapeutics is to make sure Janux is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Janux Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Janux Therapeutics' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.01460.0212
Way Down
Slightly volatile
Gross Profit Margin0.970.7581
Significantly Up
Slightly volatile
Total Current Liabilities11 M13 M
Fairly Down
Slightly volatile
Non Current Liabilities Total18.1 M23 M
Significantly Down
Slightly volatile
Total Assets251.1 M380.4 M
Way Down
Slightly volatile
Total Current Assets236.6 M349.2 M
Way Down
Slightly volatile

Janux Therapeutics F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Janux Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Janux Therapeutics in a much-optimized way.

About Janux Therapeutics Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value Per Share

8.21

At this time, Janux Therapeutics' Book Value Per Share is fairly stable compared to the past year.

Janux Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Janux Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Janux Therapeutics' managers, analysts, and investors.
Environmental
Governance
Social

About Janux Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Janux Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Janux Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Janux Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.